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Abstract
Background: Studies have been conducted on supplementing the daily diet with plant sterol ester-enriched milk
derivatives in order to reduce LDL-cholesterol levels and, consequently, cardiovascular risk. However, clinical
practice guidelines on hypercholesterolaemia state that there is not sufficient evidence to recommend their use in
subjects with hypercholesterolaemia. The main objective of this study is to determine the efficacy of the intake of
2 g of plant sterol esters a day in lowering LDL-cholesterol levels in patients diagnosed with
hypercholesterolaemia. The specific objectives are: 1) to quantify the efficacy of the daily intake of plant sterol
esters in lowering LDL-cholesterol, total cholesterol and cardiovascular risk in patients with hypercholesterolaemia;
2) to evaluate the occurrence of adverse effects of the daily intake of plant sterol esters; 3) to identify the factors
that determine a greater reduction in lipid levels in subjects receiving plant sterol ester supplements.
Methods/Design: Randomised, double-blind, placebo controlled experimental trial carried out at family doctors’
surgeries at three health centres in the Health Area of Albacete (Spain). The study subjects will be adults diagnosed
with “limit” or “defined” hypercholesterolaemia and who have LDL cholesterol levels of 130 mg/dl or over. A dairy
product in the form of liquid yoghurt containing 2 g of plant sterol ester per container will be administered daily
after the main meal, for a period of 24 months. The control group will receive a daily unit of yogurt not
supplemented with plant sterol esters that has a similar appearance to the enriched yoghurt. The primary variable
is the change in lipid profile at 1, 3, 6, 12, 18 and 24 months. The secondary variables are: change in cardiovascular
risk, adherence to the dairy product, adverse effects, adherence to dietary recommendations, frequency of food
consumption, basic physical examination data, health problems, lipid-lowering medication, physical activity,
smoking habits and socio-demographic variables.
Discussion: If plant sterol ester supplements were effective a sounder recommendation for the consumption of
plant sterols in subjects with hypercholesterolaemia could be made.
Trial Registration: Current Controlled Trials NCT01406106.
Background
Cardiovascular disease continues to be the leading cause
of death in western countries, and accounts for 33.3% of
the total deaths registered in Spain in 2004 [1]. Control
of cardiovascular risk factors is imperative for reducing
the morbidity and mortality of the population [2]. One
of these risk factors is hypercholesterolaemia, which
affects 20% of the Spanish population when considering
cholesterol levels of ≥ 250 mg/dl, and 50-69% if we con-
sider levels of ≥ 200 mg/dl [3,4]. A linear relationship
between relative cardiovascular risk and cholesterol
levels in the range of 155 to 310 mg/dL [5,6], and a con-
tinuous, gradual relationship between high cholesterol
levels and major cardiovascular risk [7,8] have been
demonstrated. * Correspondence: iparraga@sescam.jccm.es
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has instigated numerous studies. Dietary recommenda-
tions for reducing cardiovascular diseases have been
focussed on the change or reduction in fat or choles-
terol intake [9]. One of the strategies for obtaining a tai-
l o r - m a d ed i e tf o rt h i sd i s e a s ei st h eu s eo ff o o d st h a t
contain plant stanols and sterols, which reduce choles-
terol absorption [10]. Incorporating plant sterols into
the daily diet can lower lipid levels to a similar extent as
statins can, in primary prevention [11].
The generic term “functional foods” has been used for
all natural or processed food products that provide a
benefit beyond smell, flavour, texture or nutrition, and
that affect physiological functions in a measurable way
in terms of disease prevention or health promotion
[12,13]. To definitely confirm the functionality of foods,
long term clinical studies must demonstrate that their
regular consumption has a clear preventive effect on dis-
ease development. There are few controlled studies that
demonstrate the beneficial effect of the regular con-
sumption of one complete food [14].
The term phytosterols covers both plant sterols and
stanols [15]. They are plant components with a struc-
ture similar to cholesterol [16], although they are
more poorly absorbed by the intestine. They are clas-
sified into different groups depending on their struc-
ture and biosynthesis [17]. Their exact mechanism of
action and cholesterol lowering properties are not
known, but, because their structure is similar to that
of cholesterol, they compete for solubilization in the
micelles and therefore inhibit intestinal absorption of
both dietary and endogenous cholesterol [18]. They
are present in vegetable oils as regular food, although
they are also available as additives in certain foods
such as margarine or yoghurt to obtain a lipid-lower-
ing effect [19].
The regular daily intake of phytosterols ranges from
150-350 mg. A daily dose of at least 1.5 to 3 g/day has
been calculated as being the amount needed to achieve
a 10-15% reduction in low density lipoprotein choles-
terol (LDL-cholesterol). The cholesterol lowering effect
appears to level off at higher doses and no significant
benefits are obtained [20]. Several studies have demon-
strated a reduction in serum total-cholesterol and LDL-
cholesterol with the intake of foods containing stanols
and sterols [21-23].
The use of sterols combined with statins [24] and
fibrates [25] has an added affect on lowering blood cho-
lesterol levels. The favourable effect of triple therapy
(statins, sterols and cholestyramine) on cholesterol
reduction has also been evaluated [26]. Therefore, ster-
ols can also be useful in the secondary prevention of
cardiovascular disease, which requires a greater reduc-
tion in LDL-cholesterol.
A meta-analysis of 41 trials with different enriched
food products showed that the most recommendable
daily intake of phytosterols is 2 g and that this dose
reduces LDL-cholesterol by 10% [27]. A dose dependent
response relation of up to a dose of 2 g of plant sterol
or stanol a day with a reduction in LDL-cholesterol of
15 to 20 mg has also been reported [28]. However, no
effect on high density lipoprotein cholesterol (HDL-cho-
lesterol) or triglycerides was found.
Different studies have been conducted on this subject,
although very few are long term and with a large num-
ber of patients. Mensik et al. [29] performed a con-
trolled trial with 60 patients who consumed low-fat
yoghurt enriched with plant stanol esters and observed
a decrease in LDL-cholesterol of around 14%, although
the dose was higher than 3 g of stanol. Similar results
were obtained with margarine in another trial with only
34 patients for 4 weeks [20], in which a daily dose of
approximately 2 g reduced LDL-cholesterol by 12% of
the initial values. In a longer term study [30], in healthy
subjects and patients with familial hypercholesterolaemia
treated with statins and sterols, it was observed that the
cholesterol-lowering effect was maintained for 2 months.
Other studies have determined that the intake of plant
sterols in the range of 1.5 to 2.5 g/day lowers LDL-cho-
lesterol levels by 8.5-10% [27]. However, the efficacy of
new formulations to improve the solubility of plant ster-
ols and their effects on lipid reduction, as well as the
optimal frequency of their consumption throughout the
day, has not yet been investigated. The first studies on
the action of phytosterols indicated that in order to
optimise their effect they should be taken together with
cholesterol-containing food [31]. In the year 2000 a
study demonstrated that 2.5 g of plant stanols taken
once a day was just as efficacious as the same daily
amount divided over 3 meals [32].
The interest in finding new, effective strategies to
lower cholesterol and the evidence given above has led
several entities to include the consumption of these pro-
ducts in their stepped treatment of hypercholesterolae-
mia. The dietary recommendations of the USA National
Cholesterol Education Programme [33,34] include the
consumption of 2-3 g/day of phytostanols. Also the
American Heart Association (AHA) [35] recommends
foods containing stanol esters for adult patients who
need to lower their LDL-cholesterol levels, both in pri-
mary and secondary prevention. The AHA considers
stanols as a good therapeutic option, in addition to diet
and lifestyle changes, for individuals with high LDL-cho-
lesterol levels [36]. This association recommends a daily
intake of 2 g of sterols.
Several studies point that there are no significant side
effects with the intake of sterols and stanols [28,37,38].
However, it is recommended that the daily phytosterol
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information on the effects of higher intake levels [39].
Phytosterols are therefore considered safe and effective
for use as functional food ingredients [40,41]. On the
other hand, some studies have described changes in
plasma anti-oxidant concentrations [32,42] and a lower
absorption of beta carotenes associated to the consump-
tion of phytosterols has been reported [43], although the
bioavailability of liposoluble vitamins A, D and E did
not appear to be significantly changed. To minimise the
possible decrease in plasma carotene levels associated to
the consumption of sterols or stanols, the daily diet
should include vegetables and fruits [44]. The possible
implications for health are considered to be minimal
and adverse results are not expected [32]. However, a
conservative attitude is recommendable when prescrib-
ing for pregnant women, breast-feeding infants and
small children. In the European Union, the Scientific
Committee on Food has authorised the marketing of
phytosterol-enriched margarines, considering their use
at levels of up to 8% of free phytosterols, equivalent to
14% of esterified phytosterol, per 100 g of margarine is
safe for human use [45].
Although there are some data on the possible athero-
genic effect of the phytosterols [46,47], different studies
conducted in animal models and humans have demon-
strated a reduction in the atheromatous plaque after the
administration of plant sterols [48,49]. In animals a
decrease in the half life of erythrocytes and an increase
in their fragility [50,51] have been observed. The impli-
cations of these animal studies for humans are
unknown, although De Jong et al. [52] did not observe
any changes in the osmotic fragility of the erythrocyte
membranes after phytosterol consumption. Furthermore,
in the studies included in the meta-analysis by Moruisi
et al. [41] only minor digestive side effects were reported
that were not confirmed in other studies [53]. In this
respect it would also be advantageous to have results of
longer term studies.
Most studies on the efficacy of phytosterols have
been conducted outside Spain, very probably in popu-
lations with life-styles and dietary habits different from
those of the Spanish population [37]. This justifies the
need to conduct further studies in a Spanish popula-
tion; especially if we consider that the studies con-
ducted so far included few participants and had a
follow-up period of only a few weeks. Rigorous studies
a r en e e d e dt h a ta c c u r a t e l yq u a n t i f yt h em a g n i t u d eo f
the effects of phytosterols and their interaction with
other components of an individual’s diet and life-style
habits.
Stanols can play an important role in the use of diet
as a therapeutic measure. The importance of diet as a
therapeutic measure has been recognised for some
time (National Cholesterol Education Program Adults
Treatment Panel III -NCEP-ATP III-) and has been
extensively confirmed by experimental studies in
humans [54]. Since the introduction of statins, dietary
therapy has received less attention, but the growing
concern for the elevated pharmaceutical cost has led
to proposals for new alternatives for subjects with high
cholesterol levels. It would be useful to determine to
what extent combining a lipid-lowering diet with the
consumption of sterols would avoid or reduce pharma-
cological treatment in patients with mild or moderate
hypercholesterolaemia.
It has been determined [55] that some persons with
high cardiovascular risk could avoid the need for medi-
cation to lower their cholesterol levels if they made
appropriate changes to their diet. It has been demon-
strated that plant sterols and stanols lower such levels,
but it is not known if their consumption, as part of a
low-fat diet, would provide any clinically significant
additional benefit, reducing the frequency of cardiovas-
cular events.
It is appropriate, therefore, to conduct controlled stu-
dies to determine the efficacy of plant sterols and sta-
nols in persons with high cholesterol levels (primary
prevention). Studies such as the one we propose should
determine if plant stanols lower the lipid profile and
consequently reduce cardiovascular risk. In accordance
with the recommendations of the National Institute for
Health and Clinical Excellence of 2008 [55], we will con-
sider a follow up period of 2 years.
Study objectives
The general objective of our study is to determine the
efficacy of the intake of 2 g a day of plant sterol esters
in lowering LDL-cholesterol in patients diagnosed with
hypercholesterolaemia.
T h es p e c i f i co b j e c t i v e sa r e :1 )t oq u a n t i f yt h ee f f e c t
of the daily intake of plant sterol esters in lowering
LDL-cholesterol in patients with hypercholesterolaemia
at 1, 3, 6, 12, 18 and 24 months; 2) to quantify the
effect of the daily intake of plant sterol esters in lower-
ing total cholesterol in patients with hypercholestero-
laemia at 1, 3, 6, 12, 18 and 24 months; 3) to quantify
the effect of the daily intake of plant sterol esters in
reducing cardiovascular risk in patients with hypercho-
lesterolaemia at 1, 3, 6, 12, 18 and 24 months; 4) to
evaluate the occurrence of adverse effects of the daily
intake of plant sterol esters; 5) to identify the factors
that determine a greater reduction in lipid levels in
subjects receiving plant sterol ester supplements,
related to the patient’s health, dietary habits and socio-
demographic variables.
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Design
Randomised, double-blind, placebo-controlled experi-
mental trial to determine the efficacy of plant sterol
esters as dietary supplement in reducing lipids.
Study setting and subjects
Patients diagnosed with hypercholesterolaemia will be
recruited from 9 family doctors’ surgeries at 3 healthcare
centres in the health care area of Albacete, Spain.
The inclusion criteria are: a) subjects diagnosed with
limit hypercholesterolaemia (total cholesterol 200-249
mg/dl) or defined hypercholesterolaemia (total choles-
terol equal to or above 250 mg/dl) who have LDL-cho-
lesterol levels equal to or above 130 mg/dl, b) subjects
aged 18 years or over attending the participating health
centres, c) subjects who give their consent to participate
after being informed of the study objectives. The exclu-
sion criteria are: a) known hypersensitivity to sterol
esters or to the other components of the food that con-
tains them (liquid yoghurt), b) contraindication for
treatment with sterol esters or any of the components
of the food, c) physical disability that hinders collabora-
tion, d) significant chronic organic or psychiatric dis-
ease, e) not obtaining informed consent.
Sample size
To obtain a 90% statistical power with an alpha error of
0.05 (bilateral hypothesis). The effect to be demon-
strated is based on the following:
- The expected mean value of LDL-cholesterol in the
patients included in the study is 157 mg/dl ± 30 SD
(value obtained in previous studies conducted in a
Spanish population).
- To demonstrate an effect of a 10% reduction in
LDL-cholesterol in patients who receive the supple-
ments, 152 subjects are needed (76 in the active
group and 76 in the placebo group).
Assuming a 20% loss to follow up, 182 subjects will
need to be selected and will be distributed equally
between the two groups in order to obtain the maxi-
mum statistical power.
The recruitment period will be from January 2010 to
September 2010.
Formation of groups and blinding
T h es u b j e c t sw i l lb er a n d o m l ya n de q u i p r o b a b l y
assigned to the experimental or the control group. The
randomization will be generated by computer, with ran-
d o mn u m b e r sf o l l o w i n gas i z e4b l o c ks y s t e m( e n s u r e s
heterogeneity of the diet supplement administered in
the consecutive patient groups, ensuring that in each
interval exists a similar number of patients in each
group). Randomisation will be done centrally.
The containers of yoghurt (with or without the plant
sterol ester supplement) will be given to the patients in
a blinded manner. To protect the blinding, the container
of the placebo and test product will be exactly the same.
To ensure objectivity in the interpretation of the
results, the study will be conducted in a blinded manner
for the patients, investigators and data analysts. The pla-
cebo and the active product will be identical in appear-
ance and will be identified by a code, the assignment of
which will be unknown by the patients and the
investigators.
Intervention
The administration of a dairy product in the form of
liquid yoghurt, marketed in Spain, that contains 2 g per
container of plant stanol esters: sitostanol and campesta-
nol (AHA recommended dose - 1.5 to 3 g). The
enriched product and the placebo will have the same
characteristics (composition and outward appearance),
but the placebo will not contain stanol esters. The dose
will be one container a day, after the main meal, for 24
months. The participants may continue with their pre-
viously prescribed lipid-lowering treatment and new
treatment needed for this disease or for other diseases.
Composition per container: proteins 1.8 g, carbohydrates
9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin
B6 0.6 mg, folic acid 60 mg. The control group will
receive one unit a day of yoghurt not supplemented
with stanol esters that has a similar appearance to the
enriched yoghurt.
Follow-up
The subjects will be followed-up for two years.
- Selection: patients who meet the inclusion criteria
will be asked to participate in the study. After giving
their informed consent they will be given an
appointment for the initial visit and for the analytical
tests.
- Initial visit: the participant will be randomised to
one of the two groups. Their medical history will be
taken and they will be given a physical examination.
The corresponding dairy product will be dispensed
(the following doses will be dispensed according to
their expiry date). At this visit a lipid-lowering diet
will be recommended to all the participants.
- Follow-up visits: at 1, 3, 6, 12, 18, and 24 months,
the physical examination and analytical test para-
meters will be recorded. The cardiovascular risk will
be calculated and possible adverse effects and
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be recorded.
The study will be finalised for the patient in the fol-
lowing circumstances: completed follow-up period (2
years), death, violation of the protocol, adverse event,
intercurrent disease that makes it impossible to ingest
food and patient abandons study or withdraws consent.
Primary variables and measuring methods
Primary variable
- C h a n g ei nl i p i dp r o f i l ea t1 ,3 ,6 ,1 2 ,1 8a n d2 4
months. Lipid levels will be measured in both
plasma and capillary blood at the initial visit. The
validity of the capillary blood lipid levels can be
checked with the Cardiochek analyser (by total cho-
lesterol, HDL-cholesterol and triglyceride strips, and
subsequent calculation of LDL-cholesterol using the
Friedewald formula). The measurements at 3, 12 and
24 months will be in plasma. At 1, 6 and 18 months
they will only be in capillary blood.
Secondary variables
-Change in cardiovascular risk at the follow-up visits.
Systematic Coronary Risk Evaluation (SCORE) and
Gerona Heart Register (REGICOR) tables will be
used for the evaluation.
-Adherence to the dairy product (liquid yoghurt) by
self-report and Morisky-Green scale, which deter-
mines the degree of coincidence between the
patient’s behaviour and the doctor’sa d v i c e( an o n -
complier is one who answers one of the four ques-
tions of the scale inappropriately).
-Adverse events. Considered as any undesirable
event in any patient included in the study, even
though it does not have a causal relation with the
product. Known adverse events of phytosterols in
the diet at the proposed doses: occasionally mild
digestive alterations.
-Adherence to the dietary recommendations: 5-point
Likert scale.
-Frequency of food intake using the CDC-FFQ ques-
tionnaire, validated in Spain (Aguirre, 2008) consid-
ered appropriate to classify the subjects according to
their intake of food and nutrients.
-Occurrence of cardiovascular events during the fol-
low-up period: ischaemic heart disease, atherothrom-
botic cerebrovascular disease, heart failure and
peripheral artery disease.
-Weight, height, body mass index (BMI): classifica-
tion of subjects according to degree of obesity.
-Physical activity: amount of aerobic exercise
("active” if performs aerobic exercise for 30 minutes
or more, three or more times a week, “partially
active” if exercises with less frequency and for less
time that this and “inactive” when does not perform
any type of exercise).
-Smoking habit: considered smoker if answers yes to
the question “do you smoke?”
-Systolic and diastolic blood pressure (two measure-
ments): the result will be the mean of the two
measurements.
-Health problems (WONCA ICPC-2).
-Whether taking lipid-lowering pharmacological
treatment.
-Socio-demographic data: age, gender, marital status,
educational level and social class based on occupa-
tion (National Classification of Occupations).
Statistical analysis
Test of the hypothesis
The null hypothesis establishes that there is no relation-
ship between the decrease in blood LDL-cholesterol
levels and the consumption of stanol ester enriched
liquid yoghurt. The alternative hypothesis establishes a
relationship between such consumption and the inci-
dence of the primary variable.
Efficacy analysis
After the prior stages of data purification, exploratory
analysis and categorisation or transformation of vari-
ables, the following were performed:
-Comparison of the variables of interest and the
stratification and potentially confounding variables
in both groups at the start of the study. Although
we used a random assignment system, we checked
that the baseline values of the study variables were
uniform over the two groups.
-Classification of the subjects of the two groups into
different LDL-cholesterol and total cholesterol
reduction levels. A baseline raw analysis will be per-
formed to evaluate the following parameters and
their 95% confidence intervals: ABI (absolute benefit
increase), RBI (relative benefit increase) and NNT
(number needed to treat). A stratified analysis will
be performed adjusted for each independent
variable.
-The incidence of the endpoint variables in the two
groups will be described and compared at each fol-
low-up period (comparison of means using Student’s
t tests or Mann-Witney U test, depending on the
distribution of the variables). The Friedman test will
be used to compare the changes in lipid profile
throughout the study in each of the groups.
-The effect of the dairy product on total cholesterol
and LDL-cholesterol levels will be determined,
adjusted for changes in adherence to the prescribed
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means).
-The convergent validity of the capillary blood mea-
surements compared to the plasma measurements
will be analysed through intraclass correlation.
The analysis will be an intention to treat analysis
including all randomised patients in the efficacy analysis,
according to their group and regardless of the treatment
received. A per-protocol analysis will also be performed
for the primary variables. Intermediate analyses will be
performed to decide if the study should be prematurely
terminated in the event of frequent adverse effects or a
clear improvement in the test group (see Figure 1 for
the study flow chart).
Ethics Approval
This project was approved by the Research Ethics Com-
mittee of the Universitary Hospital of Albacete on May
27, 2009
Discussion
The results of this study will provide valuable informa-
tion on the efficacy of plant sterol ester supplements in
preventing cardiovascular disease by lowering plasma
cholesterol levels and consequently cardiovascular risk.
If this supplement were effective a sounder recommen-
dation for the consumption of plant sterols in subjects
with hypercholesterolaemia could be made.
Possible limitations of the study - using a randomisa-
tion procedure reduces the risk of selection bias as the
investigator will not assign treatment and any factor
that effects participation will be balanced in the two
groups. Confounding will also be reduced as randomisa-
tion tends to divide the determinant factors, which
i n f l u e n c et h ef i n a lr e s u l t ,e q u a l l yb e t w e e nt h et w o
groups. However, bias could exist on collecting
information due to the regression towards the mean
effect or tendency of the continuous variables towards
the mean in successive measurements, applicable to the
analytical results. There is also a possible risk of differ-
ential loss to follow up between the two groups, due to
the length of the study and also to the placebo effect
which could contribute to the patients abandoning the
study because they consider that the treatment provided
is not having any effect.
The study protocol has been evaluated and approved
by the Institutional Review Board of the Albacete Health
Area on 23rd April, 2009. During the performance of
the study the following ethical principles will be
respected: voluntary participation with consent of the
patient, guarantee of anonymity in the information pro-
vided by the patient, data provided by the patient exclu-
sively restricted to use in the proposed study. The
investigators will ensure that the study is conducted in
accordance with the declaration of Helsinki and with
legislation in effect (Royal Decree 223/2004) and the
New Code of Medical Ethics of the Spanish Medical
Association. The study will fully comply with Good
Clinical Practice principles.
Finally, for the development of this project the follow-
ing principles have been considered: 1) data on the dairy
product are sufficient to guarantee that the risk to the
study participants is acceptable; 2) the objectives of the
study will probably provide further knowledge of the
topic to be studied; 3) the available information warrants
the performance of this study and its potential risk to
the participants.
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